Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 77

Deep Vein Thrombosis (DVT) – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT). Deep Vein Thrombosis (DVT) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Deep Vein Thrombosis (DVT).
- A review of the Deep Vein Thrombosis (DVT) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Deep Vein Thrombosis (DVT) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Deep Vein Thrombosis (DVT) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Deep Vein Thrombosis (DVT) 9
Deep Vein Thrombosis (DVT) Therapeutics under Development by Companies 11
Deep Vein Thrombosis (DVT) Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Deep Vein Thrombosis (DVT) Therapeutics – Products under Development by Companies 18
Deep Vein Thrombosis (DVT) Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Deep Vein Thrombosis (DVT) Therapeutics Development 20
Generex Biotechnology Corporation 20
BioLineRx, Ltd. 21
Bayer AG 22
ARYx Therapeutics 23
Emisphere Technologies, Inc. 24
Merrion Pharmaceuticals Plc 25
Thrombotargets Corporation 26
Synthon Pharmaceuticals, Inc. 27
Diakron Pharmaceuticals, Inc. 28
Deep Vein Thrombosis (DVT) – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
rivaroxaban - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rivaroxaban - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
tecarfarin - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BL-5030 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TT-105 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BLX -155 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Elaprin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ardeparin sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
alteplase - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
fondaparinux sodium - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
bivalirudin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
enoxaparin sodium - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
warfarin sodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Heparin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DPOC-4088 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Deep Vein Thrombosis (DVT) Therapeutics – Drug Profile Updates 52
Deep Vein Thrombosis (DVT) Therapeutics – Discontinued Products 66
Deep Vein Thrombosis (DVT) Therapeutics - Dormant Products 67
Deep Vein Thrombosis (DVT) – Product Development Milestones 68
Featured News & Press Releases 68
Jul 25, 2012: NICE Recommends Bayer's Xarelto For Treatment Of Blood Clots 68
Jul 09, 2012: FDA Grants Priority Review For Bayer's XARELTO Supplemental NDAs 69
Jun 29, 2012: BioInvent Focuses Resources On BI-204 And New Cancer Projects 70
May 31, 2012: NICE Recommends Bayer's Xarelto To Treat Blood Clots 70
May 02, 2012: Janssen Submits XARELTO Applications To FDA For Treatment And Prevention Of Recurrent Venous Thromboembolism 71
Apr 12, 2012: Bayer Submits EU Marketing Authorization Application For Xarelto 72
Mar 19, 2012: Bayer Announces Presentation Of Phase III EINSTEIN-PE Study Results At ACC 2012 73
Mar 13, 2012: NICE Requests Bayer For More Information On Rivaroxaban To Treat Blood Clots 74
Jan 26, 2012: Watson Confirms Court Stays Preliminary Injunction 74
Jan 25, 2012: Danish Medicines Agency Completes Review For General Reimbursement Of Xarelto 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

List of Tables
Number of Products Under Development for Deep Vein Thrombosis (DVT), H2 2012 9
Products under Development for Deep Vein Thrombosis (DVT) – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Generex Biotechnology Corporation, H2 2012 20
BioLineRx, Ltd., H2 2012 21
Bayer AG, H2 2012 22
ARYx Therapeutics, H2 2012 23
Emisphere Technologies, Inc., H2 2012 24
Merrion Pharmaceuticals Plc, H2 2012 25
Thrombotargets Corporation, H2 2012 26
Synthon Pharmaceuticals, Inc., H2 2012 27
Diakron Pharmaceuticals, Inc., H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Deep Vein Thrombosis (DVT) Therapeutics – Drug Profile Updates 52
Deep Vein Thrombosis (DVT) Therapeutics – Discontinued Products 66
Deep Vein Thrombosis (DVT) Therapeutics – Dormant Products 67

List of Figures
Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2012 9
Products under Development for Deep Vein Thrombosis (DVT) – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33

- Generex Biotechnology Corporation
- BioLineRx, Ltd.
- Bayer AG
- ARYx Therapeutics
- Emisphere Technologies, Inc.
- Merrion Pharmaceuticals Plc
- Thrombotargets Corporation
- Synthon Pharmaceuticals, Inc.
- Diakron Pharmaceuticals, Inc.

Customers who bought this item also bought

• Retinal Vein Occlusion - Pipeline Review, H2 2012
• Central Retinal Vein Occlusion - Pipeline Review, H2 2012
• Deep Vein Thrombosis (DVT) - Pipeline Review, Q4 2010
• Acute Coronary Syndrome - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Hypertension - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Type 2 Diabetes - Pipeline Review, H2 2012